register free | resend password

Trials

Themenbereich / / Trials


Sortiere PresseMitteilungen nach: Titel (A\D) Datum (A\D)

Seiten sind aktuell sortiert nach: Datum (erst neue PresseMitteilungen)

Realm Therapeutics to Present at the 2017 BIO Investor Forum

MALVERN, PA -- (Marketwired) -- 10/16/17 -- Realm Therapeutics PLC (AIM: RLM)(AIM: RLM)("Realm Therapeutics", "Realm" or the "Company")Realm Therapeutics plc (AIM: RLM), a clinical stage biopharmaceutical company focused on leveraging its proprietary immunomodulatory technology, is pleased to announce that Alex Martin, CEO, will be presenting at the 2017 BIO Investor Forum on Wednesday, 18 October at 9:45 AM at the Westin St. Francis Hotel in San Francisco, CA.Mr. Martin will review the Company''s two lead drug development programmes - PR022 for Atopic ...

16.10.2017

Breaking News: CBIS/FSAO NAC Harvest Planning Session Held Yesterday Has Accelerated the Completion of the 60-acre Industrial Hemp Project Planted on the 250 acre CBIS/FSO NAC MBS001 Plot Currently Under Harvest

IRVINE, CA -- (Marketwired) -- 08/17/17 -- Cannabis Science, Inc. (OTC PINK: CBIS), a U.S. company specializing in the development of cannabinoid-based medicines, and Free Spirit Organics Native American Corporation (FSO NAC) is pleased to announce that after yesterday''s planning session the group has accelerated the completion of the 60-acre project planted on the 250-acre CBIS/FSO NAC MBS001 plot currently underway.The 2017 CBIS/FSO NAC MBS001 harvest schedule has been accelerated to immediately complete harvesting the 15-acre Phase 1 immediately. The Phase 2 harvest will begin a ...

17.08.2017

PAREXEL Collaborates With Sanofi To Advance The Use Of Wearable Devices In Life Science Industry

LONDON, June 15, 2017 - PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services organisation, today announced a collaboration with Sanofi to advance the use of wearable devices to transform the collection of data in clinical trials. Wearables have the potential to address several challenges related to clinical trials and improve execution by increasing patients’ ability to participate, driving patient engagement, and creating more opportunities for decentralised trial sites. The PAREXEL-Sanofi collaboration is designed to further explore the potential of ...

15.06.2017

Boston Therapeutics secures $1 Million financing for the first phase Multi-Centre International Ph II-III Trial

LAWRENCE, MA -- (Marketwired) -- 04/26/17 -- Boston Therapeutics, Inc. (OTCQB: BTHE) and its Asian partner Advance Pharmaceutical Company Limited, Hong Kong, announced today the fully financed new trial plans to support the safety and efficacy of BTI320, starting with a randomized, placebo-controlled, double-blinded, multi-center, international study on type 2 diabetic (T2D) patients. The study will initiate as soon as drug supply is processed and will ultimately include 300 T2D patients currently on anti-diabetic regimen. Recruitment will initiate at the Joslin Diabetes Center, Boston, MA, a ...

26.04.2017

Atossa Genetics Enrolls First Cohort of Eight Subjects in Endoxifen Study

SEATTLE, WA -- (Marketwired) -- 04/04/17 -- Atossa Genetics, Inc. (NASDAQ: ATOS) today announced that it has fully enrolled the first of six cohorts (eight participants per cohort) in its Phase 1 study of endoxifen, which is an active metabolite of tamoxifen, an FDA approved drug for breast cancer and breast cancer prevention in high risk women. The objectives of this double-blinded, placebo-controlled, repeat dose study of 48 healthy female subjects is to assess the pharmacokinetics of proprietary formulations of both oral and topical endoxifen dosage forms over 28 days, as well as to assess ...

04.04.2017

Angle PLC: Interim Results for the six months ended 31 October 2016

GUILDFORD, UNITED KINGDOM -- (Marketwired) -- 01/26/17 -- (AIM: AGL) (OTCQX: ANPCY)AIM: AGL and OTCQX: ANPCY("ANGLE" or "the Company")ANGLE plc (AIM: AGL) (OTCQX: ANPCY), the specialist medtech company, today announces its unaudited interim financial results for the six months ended 31 October 2016.Initiated two 200 patient clinical studies in Europe and the US for the Company''s first clinical application for detection of ovarian cancer in women with a high risk pelvic mass -- Interim evaluations of first 50 patients in both studies are positive (announced toda ...

26.01.2017

Taconic Biosciences Expands European Immunodeficient Animal Production

HUDSON, NY -- (Marketwired) -- 01/12/17 -- Taconic Biosciences, a global leader in genetically engineered mouse models and associated services, announced that effective January 16, 2017, the company has begun production of commercial animals in its Cologne, Germany facility. Taconic offers rodent models at a variety of health status options. This decision comes in response to increased industry demand for mouse models at more restrictive flora statuses. A key facet of Taconic''s global quality program is harmonization among all commercial facilities. The Cologne site will utilize th ...

12.01.2017

Prima BioMed Announces Data From IMP321 AIPAC Clinical Trial in Breast Cancer

SYDNEY, AUSTRALIA -- (Marketwired) -- 12/21/16 -- Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) ("Prima" or the "Company") today announced interim data from the AIPAC Phase IIb clinical trial for IMP321 in metastatic breast cancer (Active Immunotherapy PAClitaxel). The initial data confirms previous trial results showing IMP321 is safe and well tolerated.In this Phase IIb study of IMP321 plus paclitaxel chemotherapy in patients with hormone receptor-positive metastatic breast cancer, data from all 15 patients in the safety run-in phase demonstrated that IMP321 is safe and wel ...

21.12.2016

Many US Manufacturers Are Moving Too Slowly to Adopt Industry 4.0

CHICAGO, IL -- (Marketwired) -- 12/08/16 -- US manufacturers recognize the potential of Industry 4.0 to create value, but they have yet to fully appreciate the scope and magnitude of the opportunity or find the path to success, according to new research by . For example, nearly 90% of manufacturing leaders regard adopting new digital industrial technologies as a way to improve productivity, but only about one in four see opportunities to use these advances to build new revenue streams. Many are pursuing isolated initiatives scattered throughout the company, without a clear vision and coordina ...

08.12.2016

Harvard Director of Global Health Catalyst at the World-Renowned Dana Farber/Harvard Cancer Center States: Cannabis Science Presentation and Discussions a Great Success for Mutually Beneficial Partnership Opportunities with Harvard Medical School

IRVINE, CA -- (Marketwired) -- 11/21/16 -- Cannabis Science, Inc. (OTC PINK: CBIS), a U.S. company specializing in the development of cannabis-based medicines, proudly announced that following its presentation to Harvard Medical School, the Harvard Director of Global Health Catalyst at the World-Renowned Dana Farber/Harvard Cancer Center (DF/HCC), Dr. Wilfred F. Ngwa, stated: "The Cannabis Science Presentation and Discussions was a Great Success and will lead to mutually beneficial partnership opportunities between Cannabis Science and Harvard Medical School."Dr. Wilfred F. Ngwa, Di ...

21.11.2016

Tiziana Life Sciences PLC Announces Interim Results for the Six Months Ended 30 June 2016

LONDON, UNTIED KINGDOM -- (Marketwired) -- 09/29/16 -- Tiziana Life Sciences plc (AIM: TILS)(AIM: TILS)("Tiziana" or "the Company")London, 29 September 2016 - Tiziana Life Sciences plc ("Tiziana", AIM: TILS), the research and clinical stage biotechnology company focussing on proprietary drug candidates to treat cancer and autoimmune diseases, today announces its interim results for the six months ended 30 June 2016.Highlights during the period:The Company significantly enhanced its commercial and clinical development strength with the addition of highly experienc ...

29.09.2016

Flamel Technologies to Report Second Quarter 2016 Results

LYON, FRANCE -- (Marketwired) -- 07/22/16 -- Flamel Technologies (NASDAQ: FLML) today announced that the Company will report its financial results for the second quarter ended June 30, 2016 on Monday, August 8, 2016, before the market open. A conference call to discuss these results has been scheduled for Monday, August 8, 2016 at 10:00 a.m. ET. A question and answer period will follow management''s prepared remarks.To participate in the conference call, investors are invited to dial 800-930-7616 (U.S. and Canada) or 913-312-1375 (international). The conference ID number is 9799429. ...

22.07.2016

Cheoin Leisure Co., Ltd. Completes Acquisition of Units of Aurinia Pharmaceuticals Inc.

VANCOUVER, BRITISH COLUMBIA -- (Marketwired) -- 06/29/16 -- Cheoin Leisure Co., Ltd. (the "Acquiror") is pleased to announce that it has acquired 1,694,915 units (the "Units") of Aurinia Pharmaceuticals Inc. ("Aurinia") under a previously announced private placement (the "Private Placement") at US$2.36 per Unit which, based on the June 22, 2016 Bank of Canada closing exchange rate of CDN$1.2839 per U.S. dollar, equals CDN$3.03 per Unit. Each Unit comprises one common share ("Common Share") in the capital of Aurinia and 0.35 of a Common Share ...

29.06.2016

Horizon Pharma plc Announces the U.S. Patent and Trademark Office Issuance of an Additional Notice of Allowance With Claims Covering VIMOVO(R) (naproxen/esomeprazole) Delayed Release Tablets

DUBLIN, IRELAND -- (Marketwired) -- 06/01/16 -- Horizon Pharma plc (NASDAQ: HZNP), a biopharmaceutical company focused on improving patients'' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs, today announced the issuance of a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for U.S. patent application number 14/980,639, entitled "Method for Delivering a Pharmaceutical Composition to Patient in Need Thereof" that covers the U.S. approved medicine VIMOVO® (n ...

01.06.2016

Flamel Technologies Reports First Quarter 2016 Results

LYON, FRANCE -- (Marketwired) -- 05/09/16 -- Flamel Technologies (NASDAQ: FLML) today announced its financial results for the first quarter of 2016.Total revenue for first quarter 2016 was $36.2 million, compared to $32.7 million during the same period last year.GAAP net loss for the first quarter was ($6.4) million, or ($0.15) per diluted share, compared to GAAP net income of $11.6 million, or $0.27 per diluted share during the same period last year.Adjusted EBITDA was $11.8 million, compared to $12.9 million in the prior year.Adjusted net income for the first quarter was $1.6 million, or $0 ...

09.05.2016

Horizon Pharma plc Announces First-Quarter 2016 Financial Results

DUBLIN, IRELAND -- (Marketwired) -- 05/09/16 -- Horizon Pharma plc (NASDAQ: HZNP), a biopharmaceutical company focused on improving patients'' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs, announced its first-quarter 2016 financial results today and confirmed its full-year 2016 net sales and adjusted EBITDA guidance."We achieved first-quarter net sales growth of 81 percent and we expect net sales, adjusted EBITDA and operating cash flows to increase sequentially as we progress through th ...

09.05.2016

Corcept Therapeutics Announces First Quarter 2016 Financial Results and Provides Corporate Update

MENLO PARK, CA -- (Marketwired) -- 05/03/16 -- Corcept Therapeutics Incorporated (NASDAQ: CORT)First quarter revenue of $16.1 million, a 59 percent increase from the first quarter of 2015Excluding non-cash expenses, first quarter non-GAAP net income of $0.02 per share, compared to a non-GAAP net loss of $0.03 per share in the first quarter of 2015GAAP breakeven in the first quarter of 2016, compared to a GAAP net loss of $0.05 per share in the first quarter of 2015Cash balance at March 31 increases to $40.7 millionCompany reiterates 2016 revenue guidance of $76-81 millionResults expected at m ...

03.05.2016

Tiziana Life Sciences plc Tiziano Lazzaretti Appointed as Chief Financial Officer

LONDON, UNITED KINGDOM -- (Marketwired) -- 04/04/16 -- Tiziana Life Sciences plc (AIM: TILS)("Tiziana" or "the Company")London, 4 April 2016 - Tiziana Life Sciences plc (AIM: TILS, the "Company"), the clinical stage biotechnology company focused on targeted drugs to treat diseases in oncology and immunology, today announces that it has appointed Tiziano Lazzaretti as Chief Financial Officer, effective immediately. Mr Lazzaretti''s appointment is not to the Company''s board of directors.Mr Lazzaretti has extensive experience in the healthcare a ...

04.04.2016

Ritter Pharmaceuticals Doses First Patient in Phase 2b/3 Trial of RP-G28 in Lactose Intolerance

LOS ANGELES, CA -- (Marketwired) -- 03/21/16 -- Ritter Pharmaceuticals, Inc. (NASDAQ: RTTR) ("Ritter Pharmaceuticals" or the "Company"), a leading developer of novel therapeutics that modulate the human gut microbiome to treat gastrointestinal diseases, today announced the dosing of the first patient in its Phase 2b/3 clinical trial of RP-G28 for the treatment of lactose intolerance.Andrew J. Ritter, Founder and President of Ritter Pharmaceuticals, stated, "We are pleased to have initiated dosing in the Phase 2b/3 clinical trial of our lead product candidate, RP-G28 f ...

21.03.2016

Horizon Pharma plc Announces the U.S. Patent and Trademark Office Issuance of an Additional Notice of Allowance With Claims Covering RAVICTI(R) (glycerol phenylbutyrate) Oral Liquid

DUBLIN, IRELAND -- (Marketwired) -- 03/16/16 -- Horizon Pharma plc (NASDAQ: HZNP), a biopharmaceutical company focused on improving patients'' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs, today announced that it has received a Notice of Allowance from the United States Patent and Trademark Office for U.S. patent application number 14/958,259, entitled "Methods of Therapeutic Monitoring of Nitrogen Scavenging Drugs" that covers Horizon''s U.S. approved medicine RAVICTI® (g ...

16.03.2016


Page 1 from 9:  1 2  3  4  5  .. » 9





All members: 8 030
Register today: 0
Register yesterday: 0
Members online: 0
Guests online: 69


Don't have an account yet? You can create one. As registered user you have some advantages like theme manager, comments configuration and post comments with your name.